Clinical Implications of Azole-Resistant Aspergillosis in Hematological

Status Completed

Clinical Trial Summary

In order to determine the efficacy of antifungal therapy in patients with documented azole-resistant invasive Aspergillosis (IA), anonymized clinical information of patients with a hematological malignancy with a culture-positive invasive fungal infection caused by Aspergillus fumigatus are collected in an online registry. Respective fungal isolates are analysed for azole susceptibility and resistance mechanisms. Patients diagnosed with an IA in 2016 and later are included in the study.

Clinical Trial Description

For mold-active azoles (e.g. isavuconazole, itraconazole, posaconazole and voriconazole), cross-resistance of Aspergillus spp. is an increasingly recognized problem. The study aims to determine the efficacy of antifungal therapy in patients with documented azole-resistant IA. On the basis of this study, it will be possible to assess the clinical implications of IA caused by azole-resistant versus azole-susceptible Aspergillus spp. The investigators aim at collecting at least 55 azole-resistant and 130 azole-susceptible cases. Cases diagnosed with an IA by culture from January 1st, 2016 onwards with an underlying hematological malignancy are eligible for inclusion. Culture of azole-resistant cases must be provided for confirmation of the species, sequencing for azole-resistance mutations and determination of MIC using the EUCAST reference method. Isolates obtained from patients with presumed azole-susceptible disease will be analyzed to confirm the wild type phenotype. Eligible azole-resistant and azole-susceptible IA cases will be documented using the web-based case report form. If there is ≥1 resistant isolate, the patient fulfills the definition of a resistant case. Patient level data will be recorded at the respective study centres in a continuous fashion. Data items to be documented will include: demographic data; type and status of underlying conditions; concurrent immunosuppressive treatment; diagnostic measures (clinical presentation, radiology, microbiology, pathology, organ involvement); medical and surgical treatment (including prior exposure to antifungals); response to treatment (clinical and radiological) at day 14, 42, 84; overall survival at day 14, 42, 84 and at last contact; and cause of death (if applicable). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03221075
Study type	Observational [Patient Registry]
Source	University Hospital of Cologne
Contact
Status	Completed
Phase
Start date	March 1, 2017
Completion date	October 25, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06028451` - ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
Completed	`NCT00163722` - A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients	Phase 3
Completed	`NCT02394483` - Single Ascending Oral Dose Study of F901318	Phase 1
Completed	`NCT01128907` - Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients	N/A
Completed	`NCT00404092` - Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis	Phase 2
Recruiting	`NCT01386437` - Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Withdrawn	`NCT02912026` - Radiolabelled IV and Oral Metabolism Study of F901318	Phase 1
Withdrawn	`NCT03076905` - Pharmacokinetics of IV Formulation	Phase 1
Withdrawn	`NCT03095547` - Drug/Drug Interactions With F901318	Phase 1
Completed	`NCT02737371` - Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects	Phase 1
Terminated	`NCT00836875` - A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children	Phase 3
Active, not recruiting	`NCT00838643` - Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	N/A
Terminated	`NCT04876716` - Azole-echinocandin Combination Therapy for Invasive Aspergillosis	Phase 3
Recruiting	`NCT05101187` - Olorofim Aspergillus Infection Study	Phase 3
Enrolling by invitation	`NCT02104479` - Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
Not yet recruiting	`NCT05707832` - A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus	Phase 3
Recruiting	`NCT06382922` - Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
Terminated	`NCT02396225` - Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration	N/A
Recruiting	`NCT00843804` - Surveillance for Nosocomial Infections in Pediatric Cancer Patients	N/A
Completed	`NCT00334412` - COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy — CLARITY

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms